Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 2020

View Archived Issues

Mitochondria, interneurons, cognition link explored

Huntington's disease found to alter neurodevelopment

TTX-3360 selected as Triplet's first clinical candidate for repeat expansion disorders

Potent dual orexin OX1/2 receptor antagonist with improved PK profile for insomnia treatment

Phase Ib/II study of margetuximab + pembrolizumab in HER2-positive gastroesophageal adenocarcinoma

Characterization of real-time CAH degradation under pH environment of GI tract using microrheology

SOCS3 as a new therapeutic target in breast cancer

RO-7297089 demonstrates target engagement and safety in models of MM

CSF-1R as novel therapeutic target in 4T1 xenografts

SPV Therapeutics synthesizes new CDK inhibitors

Chinese investigators patent P2X3 receptor antagonists

Integral BioSciences discloses IDH1 mutant inhibitors

Dana-Farber Cancer Institute describes CDK7 inhibitors

Janssen Pharmaceutica and Johnson & Johnson present FGFR3 inhibitors

Signs of efficacy seen with DC-based cryoimmunotherapy ACT-2001 in mCRPC

Harbour BioMed presents CD73-targeting antibody HBM-1007 for immuno-oncology therapy

FibroGenesis' PneumoBlast induces reduction of lung fibrosis

New phase I/II trial explores use of DNL-310 for pediatric patients with Hunter's syndrome

TAK-676 studied alone and with pembrolizumab in new phase I study for advanced solid tumors

First phase II study of Lyme disease vaccine candidate VLA-15 meets endpoints

AdAlta begins treatment in phase I study of AD-214 for interstitial lung disease

Inotrem cleared to begin phase IIa study of nangibotide in patients with COVID-19

PTC initiates phase II/III study of PTC-299 in hospitalized participants with COVID-19

Gan & Lee opens phase Ib/II study of GLR-2007 in advanced solid tumors

UCB begins first-in-human evaluation of UCB-8600

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 12, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...